N

NYU Langone Health | Hyperbaric & Wound Care Associates

Research site

(Unclaimed)

Location

120 Mineola Boulevard, Suite 360, Mineola, New York, United States of America

Site insights

Top conditions

Top treatments

Ladarixin

BAY2927088

Androgen

Darolutamide

Olezarsen

Saline

ISIS 678354

Atezolizumab

HT-001

Parent organization

This site is a part of NYU Langone Health

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 10 total trials

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC (IMCODE003)

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorour...

Enrolling

Adenocarcinoma, Pancreatic Ductal

Drug: mFOLFIRINOX

Drug: Autogene cevumeran

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling

Biochemically Recurrent Prostate Cancer

Other: Placebo matching darolutamide

Drug: Darolutamide (BAY1841788, Nubeqa)

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling

Severe Hypertriglyceridemia

Drug: Olezarsen

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spre...

Active, not recruiting

EGFR Mutation

HER2 Mutation

Drug: BAY2927088_formulation A

Drug: BAY2927088_formulation B_2